14th Oct 2021 13:20
Tekcapital PLC - London-based intellectual property investor focused on universities - Says US Food & Drug Administration releases voluntary sodium reduction goals for the food industry, means significant milestone for portfolio company Salarius Pharmaceuticals Inc. Anticipates the move should have a positive impact on its products, business to business sales of MicroSalt and retail sales of SaltMe! crisps.
"We're very excited to see the FDA take a leadership role in encouraging the food industry to embark on meaningful sodium reduction programs for their products," says Victor Manzanilla, MicroSalt Chief Executive. "This is a major milestone for the country, and we are ready to partner with food manufacturers to help them comply with the new guidelines whilst maintaining the full-flavour of their snacks."
Current stock price: 31.00 pence, up 13% on Thursday
Year-to-date change: up 97%
By Josie O'Brien; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
TekCapital